Evidence mapPaperPMID 39887452Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2025

Evidence of Involvement of the Calcitonin Gene-Related Peptide in Restless Legs Syndrome.

Maria P Mogavero, Mojibola Fowowe, Akeem Sanni, Mona Goli, Giuseppe Lanza, Francesca L'Episcopo, Luigi Ferini-Strambi, Yehia Mechref, Raffaele Ferri

Abstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. The evolving treatment landscape of restless legs syndrome.Therapeutic advances in neurological disorders · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maria P MogaveroVita-Salute San Raffaele University, Milan, Italy.ORCID https://orcid.org/0000-0001-6662-2281
Mojibola FowoweChemistry and Biochemistry Department, Texas Tech University, Lubbock, Texas, USA.ORCID https://orcid.org/0000-0002-9168-5396
Akeem SanniChemistry and Biochemistry Department, Texas Tech University, Lubbock, Texas, USA.ORCID https://orcid.org/0000-0002-1250-7293
Mona GoliChemistry and Biochemistry Department, Texas Tech University, Lubbock, Texas, USA.ORCID https://orcid.org/0000-0001-9716-9512
Giuseppe LanzaOasi Research Institute-IRCCS, Troina, Italy.ORCID https://orcid.org/0000-0002-5659-662X
Francesca L'EpiscopoOasi Research Institute-IRCCS, Troina, Italy.ORCID https://orcid.org/0000-0003-3292-9677
Luigi Ferini-StrambiVita-Salute San Raffaele University, Milan, Italy.ORCID https://orcid.org/0000-0003-2867-5424
Yehia MechrefChemistry and Biochemistry Department, Texas Tech University, Lubbock, Texas, USA.ORCID https://orcid.org/0000-0002-6661-6073
Raffaele FerriOasi Research Institute-IRCCS, Troina, Italy.ORCID https://orcid.org/0000-0001-6937-3065

Funding

CH FoundationMinistero della Salute RC n. 2787055Robert A. Welch Foundation D-0005
6 · The paper itself

Abstract

backgroundRestless legs syndrome (RLS) is a common sensory-motor disorder characterized by an urge to move the legs, often with unpleasant sensations, particularly during rest. Current treatments include iron supplementation, dopamine agonists, and opioids, but new therapeutic approaches are needed. The dysfunction of the A11 nucleus, which modulates dopaminergic transmission to the spinal cord, is thought to play a role in RLS pathophysiology. Calcitonin gene-related peptide (CGRP), which is involved in pain modulation, may interact with A11 pathways, suggesting a role in RLS.

objectivesThis study aimed to assess the involvement of CGRP in RLS by determining if CGRP-related proteins are overexpressed in RLS patients.

methodsA cross-sectional study was conducted with 17 drug-free RLS patients (mean age 55.8 years) and 17 age- and gender-matched controls. Serum samples were analyzed using liquid chromatography-parallel reaction monitoring-tandem mass spectrometry (LC-PRM-MS/MS) to identify and quantify CGRP-related proteins. Principal component analysis (PCA) was used to differentiate between groups.

resultsPCA showed clear differentiation between RLS and control groups. Among 13 identified CGRP-related proteins, 10 were dysregulated in RLS patients: 8 were upregulated, and 2 were downregulated, among them notable proteins such as S100A12, ADM, SRSF6, and ADM2.

conclusionsThis study indicates the significant involvement of CGRP and related proteins in RLS. This suggests these proteins may play roles in various aspects of the disorder. Further research is required to validate these findings and explore their clinical implications, including development of new treatment options that specifically address CGRP pathways. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Calcitonin Gene-Related PeptideRestless Legs SyndromeAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedCalcitonin Gene-Related Peptidecalcitonin gene‐related peptide (CGRP)dopaminergic transmissionneuroinflammationproteomicsrestless legs syndrome (RLS)

Identifiers

PMID39887452
PMCPMC12160970

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.